Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Lexaria Bioscience Corp. LEXXW NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
44/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Lexaria Bioscience Corp. (LEXXW) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $705,923, +48.6%/yr average growth. Net income is $12M (loss), growing at -28%/yr. Net profit margin is -1686% (negative). Gross margin is 83.2% (+11.3 pp trend).

Balance sheet: total debt is $109,320 against $3M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 2.32 (strong liquidity). Debt-to-assets is 2.6%. Total assets: $4M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

LEXXW SharesGrow Score Overview

55/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LEXXW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
~
GROWTH Partial
58/100
LEXXW: +48.6%/yr revenue is, -28%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet LEXXW: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 2.32 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
LEXXW: Gross margin is 83.2% (+11.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
LEXXW: Net profit margin is -1686%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.0009-0.0338
Volume283.19K
Avg Volume (30D)12.49K
Market Cap$29.83K
Beta (1Y)0.48
Share Statistics
EPS (TTM)-0.66
Shares Outstanding$18M
Employees7
CEORichard C. Christopher
Financial Highlights & Ratios
Revenue (TTM)$705.92K
Gross Profit$587.35K
EBITDA$-11.8M
Net Income$-11.9M
Operating Income$-11.63M
Total Cash$1.97M
Total Debt$109.32K
Net Debt$-1.69M
Total Assets$4.18M
Price / Earnings (P/E)-0
Price / Sales (P/S)0.04
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS52886N1173

Price Chart

Track all markets on TradingView
LEXXW
Lexaria Bioscience Corp. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.00 52WK RANGE 0.03

People Also View

LEXX
LEXX
Lexaria Bioscience Corp.
$1.02
+4.08%
 RVPHW
RVPHW
Reviva Pharmaceuticals Holdings, Inc.
$0.00
-16.67%
 LIXTW
LIXTW
Lixte Biotechnology Holdings, Inc.
$0.02
+100.00%
 GOVXW
GOVXW
GeoVax Labs, Inc.
$0.00
-23.91%
 IMTXW
IMTXW
immatics biotechnologies GmbH
$0.00
-88.46%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message